Innogenetics NV v. Abbott Laboratories
Following upon a finding by the U.S. District Court for the Western District of Wisconsin that a patent held by Innogenetics was infringed by Abbott Laboratories, a jury there found that the patent, which covers a method of genotyping the hepatitis C virus, was valid. The jury also awarded Innogenetics $7 million in damages, an amount proffered at trial by Analysis Group Managing Principal John Jarosz. The award could be enhanced because the infringement was determined to be willful. Analysis Group worked with Innogenetics' outside counsel, Heller Ehrman LLP. Managing Principal Christopher Borek helped lead Analysis Group's internal team, which examined, among other things, industry licensing practices, actual and expected profits, convoyed benefits, and the strategic significance of the patent.